-
BFH772 (VEGFR2 inhibitor): Technical Guide for Angiogenesis
2026-05-21
BFH772 is a highly selective VEGFR2 inhibitor designed for researchers studying VEGFR2-driven angiogenesis, especially in tumor models. It is not suitable for protocols requiring water solubility or broad-spectrum kinase inhibition due to its defined selectivity and solubility characteristics.
-
Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S
2026-05-21
This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, capturing the complexity of the tumor microenvironment. The model improves preclinical drug testing fidelity and reveals how stromal components modulate drug response, supporting precision oncology strategies.
-
Technical Guide: EdU Flow Cytometry Assay Kits (Cy5) for S-P
2026-05-20
EdU Flow Cytometry Assay Kits (Cy5) provide an efficient method for quantifying cell proliferation by measuring S-phase DNA synthesis without harsh denaturation steps. This product is best suited for researchers requiring precise, flow cytometry-based assessment of DNA replication in intact cells. It is not intended for applications requiring tissue imaging or analysis outside compatible flow cytometric workflows.
-
Tetraethylammonium Chloride: Integrative Insights for Potass
2026-05-20
Explore how Tetraethylammonium chloride (TEAC) enables integrative studies of potassium channel function across endocrine and vascular systems. This comprehensive analysis unites mechanistic details, practical assay considerations, and translational value for advanced ion channel research.
-
CX-5461: RNA Polymerase I Inhibitor Advances in Cancer Resea
2026-05-19
CX-5461 is redefining solid tumor research by targeting ribosome biogenesis through selective RNA polymerase I inhibition. This article delivers practical workflows, troubleshooting guidance, and insights from recent studies, including its synergy with chemotherapeutics and role in autophagy and senescence induction.
-
SB 202190 in Apoptosis and Neuroprotection: Advanced Researc
2026-05-19
Explore the advanced applications of SB 202190, a potent p38 MAP kinase inhibitor, in dissecting regulated cell death and neuroprotective mechanisms. This article offers unique scientific guidance for apoptosis and inflammation research models.
-
hiPSC-Derived Intestinal Organoids in Pharmacokinetic Resear
2026-05-18
This paper introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, providing an advanced in vitro platform for pharmacokinetic studies. The approach enables more physiologically relevant modeling of drug absorption and metabolism, addressing key limitations of traditional animal models and immortalized cell lines.
-
Rotigotine’s Modulation of Bladder Function in PD Rat Models
2026-05-18
This study provides mechanistic insight into how rotigotine, a D1/D2-like dopamine receptor agonist, modulates lower urinary tract function in a rat model of Parkinson’s disease. The work reveals differential effects based on administration route and dose, with implications for non-motor symptom management in PD research.
-
Antidepressant Effects of Rotigotine in Experimental Models
2026-05-17
This study establishes rotigotine hydrochloride, a dopamine D2/D3 receptor agonist, as having measurable antidepressant-like properties in validated rodent models. The findings support the potential utility of dopaminergic modulation in depression, particularly relevant to comorbid Parkinson’s disease.
-
Eudragit® S 100-Coated Lipid Nanoparticles Enable Oral RNA D
2026-05-16
This study demonstrates that Eudragit® S 100-coated lipid nanoparticles protect RNA payloads from gastrointestinal degradation and enable efficient oral transfection in vitro. The findings highlight a novel strategy for advancing oral RNA therapeutics, overcoming major barriers in nucleic acid delivery.
-
CUDC-907: Dual PI3K and HDAC Inhibitor Protocol Guidance
2026-05-15
CUDC-907 is a dual inhibitor designed for in vitro research requiring simultaneous suppression of PI3K and HDAC signaling. It addresses the need for precise modulation of cell growth, survival, and apoptosis pathways in cancer cell models, but is not suitable for diagnostic or therapeutic applications.
-
Acetylcholine Chloride: Unveiling Gut-Brain Axis Innovations
2026-05-15
Explore how Acetylcholine Chloride empowers advanced research into the cholinergic signaling pathway and gut-brain axis. This article offers new technical insights and actionable protocol guidance for neuroscience and autonomic nervous system research.
-
XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum Chemotherap
2026-05-14
This study demonstrates that targeting XPO1 enhances the efficacy of platinum-based chemotherapy in germinal-center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) cells. By combining XPO1 inhibition with agents like cisplatin or oxaliplatin, researchers observed synergistic reductions in cell viability and increased apoptosis, suggesting a promising strategy to overcome drug resistance in relapsed or refractory DLBCL.
-
Spinal GPR30 in CCK+ Neurons Modulates Neuropathic Pain Circ
2026-05-14
This study identifies GPR30 expression in spinal cholecystokinin-positive neurons as a key modulator of neuropathic pain. The findings clarify the molecular and circuit mechanisms underlying pain hypersensitivity, offering a promising direction for targeted pain therapeutics.
-
GDF11 Dietary Supplementation Delays Aging via Smad2/3 Pathw
2026-05-13
This study demonstrates that oral intake of yeast-displayed recombinant GDF11 delays aging biomarkers and enhances antioxidant enzyme activity in aged male mice through activation of the Smad2/3 pathway. The findings clarify the mechanistic link between GDF11 signaling and oxidative stress mitigation, providing a foundation for future translational research in aging and redox biology.
446 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page